A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity

February 24, 2020
https://clinicaltrials.gov/ct2/show/NCT03962543
Cancer - Brain
Principal Investigator: Tobias Walbert, MD
PD-0325901, Neurofibromatosis, MEK 1/2 Inhibitor
Open